Adicet Bio (ACET) Assets Average (2018 - 2026)
Adicet Bio (ACET) posted quarterly Assets Average of $180.9 million for Q1 2026, down 12.09% year-over-year from $205.7 million in Q1 2025, and up 8.68% quarter-over-quarter from $166.4 million in Q4 2025.
Adicet Bio (ACET) Assets Average (2018 - 2026) Analysis & Trends
Adicet Bio's Assets Average history runs 9 years deep, the most recent figure standing at $180.9 million for Q1 2026.
- In Q1 2026, Assets Average fell 12.09% year-over-year to $180.9 million; the TTM figure through Mar 2026 stood at $180.9 million (down 12.09% YoY), while the FY2025 annual figure was $206.3 million, down 3.49% from the prior year.
- Assets Average for Q1 2026 stood at $180.9 million, up from $166.4 million in the prior quarter.
- The five-year high for Assets Average was $342.5 million in Q4 2022, with the low at $151.7 million in Q3 2025.
- The 5-year median for Assets Average is $255.4 million (2023), against an average of $255.8 million.
- The sharpest annual moves came in 2022 and 2025: Assets Average jumped 55.86% in 2022, then plunged 41.06% in 2025.
- Adicet Bio's Assets Average stood at $342.5 million in 2022, then tumbled by 35.69% to $220.3 million in 2023, then grew by 5.82% to $233.1 million in 2024, then decreased by 28.6% to $166.4 million in 2025, then gained by 8.68% to $180.9 million in 2026.
- Business Quant data shows ACET's Assets Average at $180.9 million in Q1 2026, $166.4 million in Q4 2025, and $151.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 19.82 Bn |
| 10 | Adicet Bio | 99.02 Mn | -19.17 Mn | - | 158.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 158.77 Mn |
| Mar 31, 2026 | 180.87 Mn |
| Dec 31, 2025 | 166.42 Mn |
| Sep 30, 2025 | 151.73 Mn |
| Jun 30, 2025 | 177.12 Mn |
| Mar 31, 2025 | 205.75 Mn |
| Dec 31, 2024 | 233.09 Mn |
| Sep 30, 2024 | 257.40 Mn |
| Jun 30, 2024 | 280.97 Mn |
| Mar 31, 2024 | 250.20 Mn |
| Dec 31, 2023 | 220.28 Mn |
| Sep 30, 2023 | 255.45 Mn |
| Jun 30, 2023 | 291.30 Mn |
| Mar 31, 2023 | 317.83 Mn |
| Dec 31, 2022 | 342.50 Mn |
| Sep 30, 2022 | 342.10 Mn |
| Jun 30, 2022 | 335.18 Mn |
| Mar 31, 2022 | 339.69 Mn |
| Dec 31, 2021 | 298.07 Mn |
| Sep 30, 2021 | 262.99 Mn |